Zobrazeno 1 - 10
of 7 180
pro vyhledávání: ''
Publikováno v:
Clinical Hemorheology and Microcirculation. 80:73-81
PURPOSE: The aim of this study was to evaluate the efficacy, safety and costs of ultrasound guided percutaneous radiofrequency ablation (RFA) versus open thyroidectomy for treating low-risk papillary thyroid microcarcinoma (PTMC) by using propensity
Publikováno v:
Clinical Hemorheology and Microcirculation. 79:435-444
Hyperthyroidism is a common disease mainly manifested by hyperexcitability of multiple systems and hypermetabolism. Currently, antithyroid drugs (ATDs), radioiodine therapy (RIT), and surgery are mainly used in the clinical treatment for primary hype
Autor:
Marco Schwarz, Gillian A Whitfield, A. Lühr, Christian P. Karger, Mechthild Krause, Brita Singers Sørensen, Julia Bauer, Jörg Pawelke, T S A Underwood, Neil G. Burnet, Morten Høyer, D. Wagenaar, Alexandru Dasu
Publikováno v:
Radiotherapy and Oncology
Sørensen, B S, Pawelke, J, Bauer, J, Burnet, N G, Dasu, A, Høyer, M, Karger, C P, Krause, M, Schwarz, M, Underwood, T S A, Wagenaar, D, Whitfield, G A & Lühr, A 2021, ' Does the uncertainty in relative biological effectiveness affect patient treatment in proton therapy? ', Radiotherapy and Oncology, vol. 163, pp. 177-184 . https://doi.org/10.1016/j.radonc.2021.08.016
Radiotherapy and Oncology 163(2021), 177-184
Sørensen, B S, Pawelke, J, Bauer, J, Burnet, N G, Dasu, A, Høyer, M, Karger, C P, Krause, M, Schwarz, M, Underwood, T S A, Wagenaar, D, Whitfield, G A & Lühr, A 2021, ' Does the uncertainty in relative biological effectiveness affect patient treatment in proton therapy? ', Radiotherapy and Oncology, vol. 163, pp. 177-184 . https://doi.org/10.1016/j.radonc.2021.08.016
Radiotherapy and Oncology 163(2021), 177-184
Clinical treatment with protons uses the concept of relative biological effectiveness (RBE) to convert the absorbed dose into an RBE-weighted dose that equals the dose for radiotherapy with photons causing the same biological effect. Currently, in pr
Autor:
Joshua Jones, Ima Paydar, Antony I. Koroulakis, G. Kurtz, John P. Plastaras, Jonathan Baron, Elise A. Chong, Yolanda D. Tseng, Amit Maity, Sriram Venigalla, Christopher M. Wright, Michael J. LaRiviere, Pranshu Mohindra
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:650-658
Recent improvements in chemoimmunotherapies, targeted agents, hematopoietic stem cell transplants, and cellular therapies have revolutionized treatment paradigms for patients with diffuse large B-cell lymphoma (DLBCL). Even in the relapsed or refract
Autor:
A. Salemme, Fabrizio Pane, I. Cappuccio, M.G. Rascato, Novella Pugliese, Simona Avilia, Marco Picardi, Francesco Grimaldi, A. Severino, G. Cerciello, Claudia Giordano
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e722-e725
Clinical Practice Points • MDS can occur in patients who have a history of prior exposure to chemotherapy and/or radiotherapy for a previous lymphoma. • MDS can occur with autoimmune disorders not responsive to immunosuppressive treatments. • C
Autor:
Eunice S. Wang, Nicholas J. Short, Guido Marcucci, Amir T. Fathi, Hagop M. Kantarjian, Andrew H. Wei, Martin S. Tallman, Farhad Ravandi
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:580-597
With the Food and Drug Administration approval of 9 agents for different acute myeloid leukemia (AML) indications, the prognosis and management of AML is evolving rapidly. Herein, we review the important milestones in the history of AML research and
Autor:
Tara Cronin, Kristopher Attwood, Eunice S. Wang, Sarah Sadek, Mark G. Faber, Swapna Thota, James E. Thompson, Jeffrey Baron, Ellen Madarang, Elizabeth A. Griffiths, Justin M. Watts, Terrence Bradley, Amanda Przespolewski, Abhay Singh
Publikováno v:
Clin Lymphoma Myeloma Leuk
The optimal approach to combine gemtuzumab-ozogamicin (GO) with various chemotherapy backbones and other newer agents safely remains to be determined. We performed a retrospective analysis of the safety and outcomes of newly diagnosed adult AML patie
Autor:
Manfred Schmidt, Maximilian Zaussinger, Georg M. Huemer, Dominik Duscher, Raphael Wenny, Isabel Zucal
Publikováno v:
Clinical Hemorheology and Microcirculation. 78:283-290
BACKGROUND: The length of the amputation stump is crucial for optimal prosthetic fitting and rehabilitation. Especially in traumatic amputation, direct closure of the stump may be challenging, and bone shortening is frequently needed. To avoid excess
Autor:
Qinglin Rong, Li Zhu, Chang-Ying Ma, Jing Cheng, Yu Tang, Jun Zhang, Min Liu, Weihu Wang, Jiayi Chen, Zhou Huang, Hong-Fen Wu, Liang-Fang Shen, Yexiong Li, Xiaobo Huang, Mei Shi, Shulian Wang, Jian Tie
Publikováno v:
Radiotherapy and Oncology. 161:191-197
Background This study aimed to establish a nomogram for predicting locoregional recurrence (LRR) in breast cancer patients treated with neoadjuvant chemotherapy (NAC) and mastectomy. Methods A total of 2368 patients who received NAC and mastectomy be
Autor:
Stéphanie Servagi, Pascale Mere, Eliane Tang, William Kao, Florence Huguet, Céline David, Mélanie Deberne, Laurent Quero, Marc-André Mahé, Nicolas Meillan, Audrey Keller, Véronique Vendrely, Nicolas Magné, Yoann Pointreau, Sophie Roca, Laurence Moureau-Zabotto, David Atlani, A. Orthuon, Bertrand Chaulin, Didier Peiffert, Olivier Bouché, Charles Debrigode, Paul Sargos, Hortense Laharie, Bruno Lamezec, Paul Chauchat, Séverine Racadot, Claire Lemanski, Jérôme Doyen
Publikováno v:
Radiotherapy and Oncology. 161:198-204
Purpose The aim of this study is to correlate locoregional relapse with radiation therapy volumes in patients with rectal cancer treated with neoadjuvant chemoradiation in the ACCORD 12/0405-PRODIGE 02 trial. Patients and methods We identified patien